Royalty Pharma (RPRX) Insider Bonnie Bassler Buys $37K of Stock
Bonnie Bassler purchased 689 shares of Royalty Pharma, totaling around $37,482, as the stock trades at $56.07.
Reviewed by automated data checks against the source filing. How we make and check alerts
Bonnie Bassler bought 689 shares of Royalty Pharma plc ($RPRX) at an average price of $54.40, worth about $37,481.60, on June 30, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RPRX is up 3.1% after 1 week, up 5.3% after 1 month and up 9.2% to date (from the $55.84 close on Jun 30, 2026).
RPRX
Royalty Pharma plc
Key Points
- Bonnie Bassler bought 689 shares of Royalty Pharma plc (NasdaqGS: RPRX) for about $37,482 on June 30, 2026.
- The stock is currently trading at $56.07, down from $58.41 at the previous close, indicating a recent dip.
- Analysts maintain a strong buy consensus on Royalty Pharma, with a target mean price of $65.13 based on eight opinions.
Get $RPRX trade alerts by text
We text you when insiders, Congress or big funds trade $RPRX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Royalty Pharma plc alert may contain errors. Disclosures
Insider Buying and Selling at Royalty Pharma plc
On June 30, 2026, Bonnie Bassler purchased 689 shares of Royalty Pharma plc (NasdaqGS: RPRX) for about $37,482. This buy adds to her existing stake as the stock trades at $56.07, down from its previous close of $58.41.
Details of the Transaction
Bassler bought these shares at an average price of $54.40. This move reflects her ongoing belief in the company's potential and its position within the biotechnology sector. With the shares now at approximately $56.07, this purchase may influence market perception regarding her confidence in Royalty Pharma's prospects.
Analysts Set New Price Targets
Recent analyst ratings show robust support for Royalty Pharma. On October 7, 2026, Morgan Stanley maintained an Overweight rating with a price target of $67.00. TD Cowen also kept a Buy rating, increasing its target to $68.00 on September 8, 2026. JP Morgan affirmed its Overweight rating on August 7, 2026, adjusting its target to $62.00. Overall, the consensus from eight analysts gives Royalty Pharma a strong buy recommendation, with a mean target of $65.13.
What Royalty Pharma plc Does
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry. The company has royalties on about 35 marketed therapies and supports numerous development-stage candidates across various therapeutic areas, including oncology and rare diseases.
What's Ahead for Royalty Pharma plc
Royalty Pharma is scheduled to announce its next earnings report on November 4, 2026. Investors will be watching for this update, especially after the recent insider transaction. Remember that the recent Form 4 filings only reflect past trades and may not represent the current positions of insiders.
Related Filing Alerts
Source: Bonnie Bassler's Form 4 filing on $RPRX (Jun 30, 2026). Find the original filing: RPRX Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts